Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Zhenyuan Biotech Co. Ltd. is navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. HUTSON, RICHARD G is the busiest examiner, currently reviewing the pending matter.
The involvement of only 1 distinct art unit suggests that the company's current prosecution is focused within a single technical specialty. This 1 action requires a specialized response tailored to the standards of the assigned unit. For a practitioner, the concentration under a single examiner allows for a more direct dialogue with the USPTO, which can lead to a more efficient resolution of technical rejections.
In the Biotechnology & Pharmaceuticals sector, maintaining a unified prosecution record is often critical for securing valuable patent rights. Since the company is only dealing with a distinct examiner, the risk of inconsistent claim interpretations across the portfolio is minimized. This centralized review process allows the applicant to focus resources on the specific requirements and examination style of the assigned official, ensuring a more predictable path for the pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037752 | USE OF FATTY ACID ELONGASE GENE AND ESTERASE GENE IN SYNTHESIS OF NERVONIC ACID AND GREASE IN YEAST | HUTSON, RICHARD G | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037752 | USE OF FATTY ACID ELONGASE GENE AND ESTERASE GENE IN SYNTHESIS OF NERVONIC ACID AND GREASE IN YEAST | HUTSON, RICHARD G | 1652 | §102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Zhenyuan Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Richard G Hutson has the most, with 1 of Zhejiang Zhenyuan Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
